.jpeg)
{{ variable.name }}
Psoriasis is an immune-mediated chronic, systemic, inflammatory disease, and its core pathogenesis is regulated by the JAK-STAT pathway mediated by the Janus kinase (JAK) family.
1. Generic name: Deucravacitinib
2. Trade name: SOTYKTU™
1. For the treatment of adult patients with moderate to severe plaque psoriasis who are suitable for systemic treatment or phototherapy.
2. Restricted use: It is not recommended to use it in combination with other powerful immunosuppressants.
6 mg, tablets
1. Each tablet contains 6 mg of deuterated colexitinib.
2. Excipients include: anhydrous lactose, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and silicon dioxide.
1. The recommended dose is 6 mg taken orally once a day, which can be taken with food or on an empty stomach.
2. The tablet should be swallowed whole and should not be crushed, cut or chewed.
3. If you miss a dose, there is no need to take it again. Take the next dose according to the originally planned time.
1. Patients with mild to moderate hepatic insufficiency (Child-Pugh A or B) do not need to adjust the dose.
2. It is not recommended for patients with severe hepatic insufficiency (Child-Pugh C grade).
3. Patients with renal insufficiency (including those with end-stage renal disease requiring dialysis) do not need to adjust the dose.
1. Medication time: Take the medication at a fixed time every day, not affected by food.
2. Swallowing requirements: Swallow the whole tablet without damaging the tablet structure.
3. Treatment of missed doses: Do not make up for missed doses and continue taking the medicine as originally planned.
4. Tuberculosis screening, vaccination evaluation and liver function tests are required before treatment.
5. Avoid using it at the same time with live vaccines.
6. If symptoms such as infection, muscle pain, allergic reaction, etc. occur during treatment, you should seek medical treatment in time.
1. Pregnant women: The available data are insufficient and animal experiments have not shown embryotoxicity, but it should be used with caution.
2. Breastfeeding women: The drug may be secreted with breast milk and is not recommended for use during breastfeeding.
3. Children: Safety and effectiveness have not been established.
4. The elderly (≥65 years old):The risk of infection and serious adverse reactions is higher and close monitoring is required.
5. Hepatic insufficiency: It is contraindicated in severe patients, and no dose adjustment is required for mild to moderate patients.
6. Renal insufficiency: No dose adjustment is required, including dialysis patients.
1. Upper respiratory tract infection
2. Increased blood creatine phosphokinase (CPK)
3. Herpes virus infection (such as herpes simplex)
4. Oral ulcers
5. Folliculitis
6. Acne
h4>
1. Severe allergic reactions (such as angioedema)
2. Infections (such as pneumonia, COVID-19, tuberculosis)
3. Malignant tumors (including lymphoma)
4. Rhabdomyolysis
5. Elevated liver enzymes
6. Elevated blood lipids (triglycerides)
It is prohibited for those allergic to deuterated coxitinib or any excipients.
1. Avoid simultaneous use with live vaccines.
2. No significant interactions were found when combined with drugs such as cyclosporine, fluvoxamine, ritonavir, diflunic acid, pyrimethamine, famotidine or rabeprazole.
3. No clinically relevant effects have been seen when combined with rosuvastatin, methotrexate, mycophenolate mofetil or oral contraceptives.
1. Store at 20°C to 25°C (68°F to 77°F). Short-term storage is allowed at 15°C to 30°C (59°F to 86°F).
2. Keep the medicine intact and avoid moisture, high temperature and light.